Article Image
IPFS News Link • Vaccines and Vaccinations

Small Percent of Vaccine Batches Responsible for Large Number of Adverse Reactions, Analysts Claim

• https://www.globalresearch.ca, By Patrick Delaney

A recent analysis of public government data reveals very high percentages of adverse events reported as a result of COVID-19 experimental "vaccine" injections, including over 21,000 deaths, have occurred in a small minority of product batches released by pharmaceutical manufacturers.

Furthermore, according to analysts, the wide dispersement of these highly toxic batches (or "lots") to numerous U.S. states, along with their apparent sequential labeling according to levels of toxicity, is evidence of intentionality in  adulterating the contents of the shots and is thus likely a serious violation of federal regulations that require such products to have consistency.

In mid-November, London-based researcher Craig Paardekooper produced a short video drawing data from the  Vaccine Adverse Event Reporting System (VAERS) in the United States, where he discovered that "1 in 200 of the [COVID-19 vaccine] batches are highly toxic," while the vast majority of them are not, at least according to short-term outcomes.

"In fact," he continued, "70% of the batches for the vaccine-only produce one adverse reaction report in total," and "80% of the vaccine batches only produce one or two adverse reaction reports."

However, Paardekooper began to find anomalies that "produced thousands of times the number of adverse reactions" standing out from the vast majority of batches, including examples of 1,394, 1,012, and eventually to as many as 4,911 adverse reactions.

Additionally, these batches consistently produced these injuries across the many states where they were distributed, affirming the cause was the vaccine contents in the batches themselves rather than local circumstances, applications or demographics.

For example, for Pfizer, only 4% of their lots accounted for all the death reports associated with those injections and for Moderna the same was true with respect to only 5% of their batches.